Develops antibody therapeutics by leveraging deep learning and adaptive immunity to identify and replicate antibodies from resilient individuals, such as long-term cancer survivors. This approach targets hard-to-treat diseases, providing a potential solution for conditions like Parkinson’s disease.

Allay Therapeutics develops targeted analgesic formulations specifically designed for post-surgical pain management, utilizing a proprietary delivery system to enhance absorption and efficacy. Their products aim to reduce opioid reliance and improve patient recovery outcomes following surgical procedures.

Amber Therapeutics is developing the Picostim™ System, a fully implantable device that utilizes adaptive pudendal neuromodulation to treat mixed urinary incontinence by dynamically stimulating the pudendal nerve based on real-time physiological feedback. This therapy addresses the significant unmet need of over 40 million women in the U.S. suffering from this debilitating condition, with promising clinical results demonstrating improved quality of life.

Atsena Therapeutics is a clinical-stage gene therapy company utilizing adeno-associated virus (AAV) technology to develop treatments for inherited retinal diseases, specifically targeting X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Their ongoing Phase I/II clinical trials aim to reverse or prevent vision loss in patients suffering from these genetic conditions.

Bonito Biosciences provides an AI‑driven platform that designs small‑molecule ligands for targeted delivery of oligonucleotide therapeutics such as siRNA and antisense oligonucleotides. The modular chemistry system enables covalent attachment of these payloads to ligands that bind receptors on virtually any tissue, delivering preclinical data on biodistribution, efficacy, and safety to help pharma and biotech developers reach non‑hepatic organs.

Cardiac Booster develops a next-generation, high-flow, low-profile percutaneous ventricular assist device (pVAD). This minimally invasive device provides temporary hemodynamic support for patients experiencing cardiogenic shock or undergoing high-risk PCI. The technology aims to improve patient outcomes by offering effective cardiac assistance with reduced procedural invasiveness.

Carrick Therapeutics develops targeted cancer therapies that combine CDK12/13 inhibitors with existing oncology drugs to treat aggressive forms of breast, prostate, and ovarian cancers. Their approach addresses the challenge of treatment resistance in advanced cancer patients, aiming to improve clinical outcomes through innovative combination therapies.

Cerevance utilizes its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify novel therapeutic targets for neurological diseases, including Parkinson's and Alzheimer's. The company develops cell type-specific therapies aimed at addressing the unmet medical needs associated with neurodegenerative and psychiatric disorders.

Crystalys Therapeutics focuses on developing new therapeutics to address significant unmet medical needs for people living with gout. The company is actively advancing its pipeline through clinical development, including ongoing Phase 3 studies. Their work aims to provide improved treatment options for patients managing this condition.

FIRE1 is developing novel therapeutic devices aimed at enhancing patient outcomes through targeted delivery mechanisms. The startup addresses the need for more effective treatment options in the medical device sector, focusing on improving therapeutic efficacy and patient compliance.

MediSix Therapeutics develops proprietary T-cell therapies, utilizing their unique Protein Expression BLocker (PEBL) technology to enhance T-cell function for patients with T-cell malignancies. The company addresses the limitations of existing CAR T-cell therapies, aiming to improve treatment outcomes for complex and rare cancers and autoimmune diseases.

The startup develops novel immunotherapeutics targeting autoimmune disorders and inflammatory diseases through the creation of immunomodulatory compounds. By providing effective therapeutic options, the company aims to enhance treatment accessibility for patients and healthcare providers dealing with these chronic conditions.

ProVerum Medical develops minimally invasive devices utilizing a proprietary technology to treat benign prostatic hyperplasia, a condition that causes urinary obstruction in men. Their approach aims to reduce patient recovery time and minimize complications associated with traditional surgical methods.

Reprieve Cardiovascular offers the Reprieve System, a personalized intelligent decongestion management solution that utilizes real-time patient data to optimize diuretic therapy for acute decompensated heart failure patients. This system addresses the challenge of fluid overload, which accounts for 83% of heart failure hospitalizations, by providing physicians with enhanced visibility and control over treatment decisions.

Shoulder Innovations develops InSet™ Glenoid fixation technology, which utilizes a proprietary curved fin geometry and interlock porous coating to enhance rotational stability and promote bony ingrowth. This technology addresses the issue of inadequate fixation in traditional shoulder arthroplasty, improving procedure longevity and patient outcomes.

This company develops antibody-based imaging and therapy technology to enhance cancer treatment efficacy. Their platform enables selective chemical manipulation of tagged antibodies in vivo, improving radioimmuno-imaging, therapy, and antibody-drug conjugates for more effective and lower-dose imaging.

Tallac Therapeutics develops antibody-drug conjugates (ADCs) that utilize Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to deliver TLR9 agonists directly to tumors, enhancing immune activation within the tumor microenvironment. Their approach addresses the challenge of ineffective immune responses in cancer treatment by enabling precise and systemic delivery of oligonucleotide-based therapies.

Trishula Therapeutics is developing TTX-030, a first-in-class anti-CD39 antibody that targets immune evasion mechanisms in the tumor microenvironment to enhance anti-tumor immune responses. This approach aims to prevent immune suppression caused by extracellular adenosine, thereby improving treatment outcomes for patients with metastatic pancreatic cancer and other solid tumors.

Trotana Therapeutics is focused on discovering and developing therapeutics that target RNA binding proteins to address unmet medical needs across various indications. By leveraging expertise in this novel field, the company aims to create effective treatments for conditions that currently lack viable options.

Vigil Neuroscience develops microglia-targeted therapeutics that activate TREM2, a receptor crucial for maintaining brain homeostasis, to address neurodegenerative diseases linked to microglial dysfunction. By employing a precision medicine approach, the company aims to create targeted drug candidates for genetically defined patient subpopulations, ultimately expanding to broader patient populations.

Volta Medical develops AI-driven software that assists cardiologists by analyzing electrophysiology data during interventional procedures. This technology enhances procedural accuracy and decision-making, ultimately improving patient outcomes in cardiac care.